Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

SALUTENSIN

HYDROFLUMETHIAZIDE; RESERPINE

Standard Dose
50MG;0.125MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview SALUTENSIN is listed in Drugs@FDA under application 012359 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient HYDROFLUMETHIAZIDE; RESERPINE Form and strength TABLET;ORAL - 50MG;0.125MG Sponsor SHIRE Submission history Latest submission status date: 1996-06-24 00:00:00.

Structured Monograph

Clinical summary

Approval overview SALUTENSIN is listed in Drugs@FDA under application 012359 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient HYDROFLUMETHIAZIDE; RESERPINE Form and strength TABLET;ORAL - 50MG;0.125MG Sponsor SHIRE Submission history Latest submission status date: 1996-06-24 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.